(Total Views: 632)
Posted On: 07/29/2025 3:17:38 PM
Post# of 155721
From Reddit yesterday :
r/Livimmune
•
rogex2
Celcuity Stock Triples on Positive Breast Cancer Treatment Study ($13.77 close, $45.96 open)
https://www.stocktitan.net/news/CELC/celcuity...sygrr.html
Unprecedented 76% reduction in disease progression risk with gedatolisib triplet therapy
Significant 7.3-month improvement in median PFS for triplet therapy vs. control
67% reduction in disease progression risk with gedatolisib doublet therapy
Lower treatment discontinuation rates compared to Phase 1b and other Phase 3 trials
Better safety profile with lower rates of hyperglycemia and stomatitis
First PI3K/AKT/mTOR pathway inhibitor showing positive Phase 3 results in PIK3CA wild-type patients
Not TNBC, but the median PFS pales in comparison to therapy with LL added.
IMO
CELC shares ~38 million = a bigger pop than CYDY would initially expect. However a Progression Free survival of 5 years, when proven, will put CYDY SP well past what CELC is trading at today.
r/Livimmune
•
rogex2
Celcuity Stock Triples on Positive Breast Cancer Treatment Study ($13.77 close, $45.96 open)
https://www.stocktitan.net/news/CELC/celcuity...sygrr.html
Unprecedented 76% reduction in disease progression risk with gedatolisib triplet therapy
Significant 7.3-month improvement in median PFS for triplet therapy vs. control
67% reduction in disease progression risk with gedatolisib doublet therapy
Lower treatment discontinuation rates compared to Phase 1b and other Phase 3 trials
Better safety profile with lower rates of hyperglycemia and stomatitis
First PI3K/AKT/mTOR pathway inhibitor showing positive Phase 3 results in PIK3CA wild-type patients
Not TNBC, but the median PFS pales in comparison to therapy with LL added.
IMO
CELC shares ~38 million = a bigger pop than CYDY would initially expect. However a Progression Free survival of 5 years, when proven, will put CYDY SP well past what CELC is trading at today.
(8)
(0)
